Cedazuridine
- Generic Name
- Cedazuridine
- Brand Names
- Inqovi 5 Tablet Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C9H14F2N2O5
- CAS Number
- 1141397-80-9
- Unique Ingredient Identifier
- 39IS23Q1EW
- Background
Myelodysplastic syndromes (MDS) are a group of hematopoietic neoplasms that give rise to variable cytopenias progressing to secondary acute myeloid leukemia (sAML), which is invariably fatal if untreated. Hypomethylating agents such as decitabine and azacitidine are used to treat MDS through inducing DNA hypomethylation and apoptosis of cancerous cells. Alth...
- Indication
Cedazuridine, in combination with decitabine, is indicated for the treatment of myelodysplastic syndromes (MDS), including MDS with refractory anemia, MDS with refractory anemia and ringed sideroblasts, MDS with refractory anemia and excess blasts, MDS scoring intermediate-1, intermediate-2, or high-risk on the International Prognostic Scoring System (IPSS),...
- Associated Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Associated Therapies
- -
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06597734
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Sanjay Mohan
- Target Recruit Count
- 51
- Registration Number
- NCT05799079
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Takeda
- Registration Number
- NCT04985656
Thorough QT Assessment of Cedazuridine in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04953923
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 317
- Registration Number
- NCT04256317
- Locations
- 🇺🇸
Keck School of Medicine of USC, Los Angeles, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸MedStar Georgetown University Hospital, Washington, District of Columbia, United States
Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2024-12-16
- Target Recruit Count
- 29
- Registration Number
- NCT03875287
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.